Treatment Comparison for Soft Tissue Sarcoma

What we are studying

Researchers want to find out if an investigational drug (study drug) can help patients with advanced soft tissue sarcoma when it is combined with doxorubicin. The purpose of this study is to gather information on the safety of the study drug in combination with doxorubicin (routine treatment) and how it will affect this type of cancer. The study will also look at how the drug is processed in the body.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 15+

Eligibility Criteria

  • Diagnosed with soft tissue sarcoma

What is involved

  • Participant will last about 6 months
  • Screening period up to 3 weeks
  • Up to 6 cycles of treatment (2 weeks for each cycle)
  • 1 follow-up visit 1-2 weeks after last treatment
  • Phone call follow-up every 12 weeks for 3 years

Compensation

None

Contact Information

Study Coordinator
Jennifer Black
Email
jhblack@wakehealth.edu
Phone
336-716-9342

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.